Genetic and epigenetic-sensitive regulatory network in immune response: a putative link between HLA-G and diabetes

References

• Carosella ED. The tolerogenic molecule HLA-G. Immunol Lett. 2011;138:22–24.
   PubMed Web of Science ®Google Scholar
• Coupel S, Moreau A, Hamidou M, et al. Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood. 2007;109:2806–2814.
   PubMed Web of Science ®Google Scholar
• Alegre E, Rizzo R, Bortolotti D, et al. Some basic aspects of HLA-G biology. J Immunol Res. 2014;2014:657625.
   PubMed Web of Science ®Google Scholar
• Rouas-Freiss N, Gonçalves RM, Menier C, et al. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci U S A. 1997;94:11520–11525.
   PubMed Web of Science ®Google Scholar
• Cirulli V, Zalatan J, McMaster M, et al. The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G. Diabetes. 2006;55:1214–1222.
   PubMed Web of Science ®Google Scholar
• Gregori S, Tomasoni D, Pacciani V, et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood. 2010;116:935–944.
   PubMed Web of Science ®Google Scholar
• López AS, Alegre E, Díaz-Lagares A, et al. Effect of 3-hydroxyanthranilic acid in the immunosuppressive molecules indoleamine dioxygenase and HLA-G in macrophages. Immunol Lett. 2008;117:91–95.
   PubMed Web of Science ®Google Scholar
• Carosella ED, HoWangYin KY, Favier B. HLA-G-dependent suppressor cells: diverse by nature, function, and significance. Hum Immunol. 2008;69:700–707.
   PubMed Web of Science ®Google Scholar
• Carosella ED, Rouas-Freiss N, Tronik-Le Roux D, et al. HLA-G: an immune checkpoint molecule. Adv Immunol. 2015;127:33–144.
   PubMed Web of Science ®Google Scholar
• Pistoia V, Morandi F, Wang X, et al. Soluble HLA-G: are they clinically relevant? Semin Cancer Biol. 2007;17:469–479.
   PubMed Web of Science ®Google Scholar
• Bortolotti D, Gentili V, Rotola A, et al. Impact of HLA-G analysis in prevention, diagnosis and treatment of pathological conditions. World J Methodol. 2014;4:11–25.
   PubMedGoogle Scholar
• Sommese L, Paolillo R, Cacciatore F, et al. HLA-G and anti-HCV in patients on the waiting list for kidney transplantation. Adv Med Sci. 2018;63:317–322.
   PubMed Web of Science ®Google Scholar
• Sommese L, Benincasa G, Lanza M, et al. Novel epigenetic-sensitive clinical challenges both in type 1 and type 2 diabetes. J Diabetes Complications. 2018;32:1076–1084.
   PubMed Web of Science ®Google Scholar
• Baffy G, Loscalzo J. Complexity and network dynamics in physiological adaptation: an integrated view. Physiol Behav. 2014;131:49–56.
   PubMed Web of Science ®Google Scholar
• Sharma A, Halu A, Decano JL, et al. Controllability in an islet specific regulatory network identifies the transcriptional factor NFATC4, which regulates type 2 diabetes associated genes. NPJ Syst Biol Appl. 2018;4:25.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang T, Liu H, et al. Detection of type 2 diabetes related modules and genes based on epigenetic networks. BMC Syst Biol. 2014;8:1–5.
   PubMed Web of Science ®Google Scholar
• Gong R, Chen M, Zhang C, et al. A comparison of gene expression profiles in patients with coronary artery disease, type 2 diabetes, and their coexisting conditions. Diagn Pathol. 2017;12:44.
   PubMed Web of Science ®Google Scholar
• Leopold JA, Loscalzo J. Emerging role of precision medicine in cardiovascular disease. Circ Res. 2018;122:1302–1315.
   PubMed Web of Science ®Google Scholar
• Castelli EC, Veiga-Castelli LC, Yaghi L, et al. Transcriptional and posttranscriptional regulations of the HLA-G gene. J Immunol Res. 2014;2014:734068.
   PubMed Web of Science ®Google Scholar
• Castelli EC, Gerasimou P, Paz MA, et al. HLA-G variability and haplotypes detected by massively parallel sequencing procedures in the geographicaly distinct population samples of Brazil and Cyprus. Mol Immunol. 2017;83:115–126.
   PubMed Web of Science ®Google Scholar
• Leisegang MS, Gu L, Preussner J, et al. The histone demethylase PHF8 facilitates alternative splicing of the histocompatibility antigen HLA-G. FEBS Lett. 2019. DOI:10.1002/1873-3468.13337.
   PubMed Web of Science ®Google Scholar
• Tronik-Le Roux D, Renard J, Vérine J, et al. Novel landscape of HLA-G isoforms expressed in clear cell renal cell carcinoma patients. Mol Oncol. 2017;11:1561–1578.
   PubMed Web of Science ®Google Scholar
• Díaz-Lagares A, Alegre E, LeMaoult J, et al. Nitric oxide produces HLA-G nitration and induces metalloprotease-dependent shedding creating a tolerogenic milieu. Immunology. 2009;126:436–445.
   PubMed Web of Science ®Google Scholar
• Rousseau P, Le Discorde M, Mouillot G, et al. The 14 bp deletion-insertion polymorphism in the 3ʹ UTR region of the HLA-G gene influences HLA-G mRNA stability. Hum Immunol. 2003;64:1005–1010.
   PubMed Web of Science ®Google Scholar
• Dias FC, Bertol BC, Poras I, et al. The genetic diversity within the 1.4 kb HLA-G 5ʹ upstream regulatory region moderately impacts on cellular microenvironment responses. Sci Rep. 2018;8:5652.
   PubMed Web of Science ®Google Scholar
• Castelli EC, Mendes-Junior CT, Veiga-Castelli LC, et al. A comprehensive study of polymorphic sites along the HLA-G gene: implication for gene regulation and evolution. Mol Biol Evol. 2011;28:3069–3086.
   PubMed Web of Science ®Google Scholar
• Yie SM, Li LH, Xiao R, et al. A single base-pair mutation in the 3ʹ-untranslated region of HLA-G mRNA is associated with pre-eclampsia. Mol Hum Reprod. 2008;14:649–653.
   PubMed Web of Science ®Google Scholar
• Castelli EC, Moreau P, Oya E Chiromatzo A, et al. In silico analysis of microRNAs targeting the HLA-G 3ʹ untranslated region alleles and haplotypes. Hum Immunol. 2009;70:1020–1025.
   PubMed Web of Science ®Google Scholar
• de Almeida BS, Muniz YCN, Prompt AH, et al. Genetic association between HLA-G 14-bp polymorphism and diseases: A systematic review and meta-analysis. Hum Immunol. 2018;79:724–735.
   PubMed Web of Science ®Google Scholar
• Martelli-Palomino G, Pancotto JA, Muniz YC, et al. Polymorphic sites at the 3ʹ untranslated region of the HLA-G gene are associated with differential HLA-G soluble levels in the Brazilian and French population. PLoS One. 2013;8:e71742.
   PubMed Web of Science ®Google Scholar
• Eike MC, Becker T, Humphreys K, et al. Conditional analyses on the T1DGC MHC dataset: novel associations with type 1 diabetes around HLA-G and confirmation of HLA-B. Genes Immun. 2009;10:56–67.
   PubMed Web of Science ®Google Scholar
• de Albuquerque RS, Mendes-Junior CT, Lucena-Silva N, et al. Association of HLA-G 3ʹ untranslated region variants with type 1 diabetes mellitus. Hum Immunol. 2016;77:358–364.
   PubMed Web of Science ®Google Scholar
• Gerasimou P, Skordis N, Picolos M, et al. HLA-G 14-bp polymorphism affects the age of onset in type I diabetes mellitus. Int J Immunogenet. 2016;43:135–142.
   PubMed Web of Science ®Google Scholar
• Silva HP, Ururahy MA, Souza KS, et al. The association between the HLA-G 14-bp insertion/deletion polymorphism and type 1 diabetes. Genes Immun. 2016;17:13–88.
   PubMed Web of Science ®Google Scholar
• Rezaei F, Zareei N, Razmi N, et al. Genetic Polymorphism of HLA-G 14-bp insertion/deletion in pancreas transplant recipients and its association with type 1 diabetes mellitus. Exp Clin Transplant. 2019. DOI:10.6002/ect.2018.0162
   PubMed Web of Science ®Google Scholar
• Sommese L, Zullo A, Mancini FP, et al. Clinical relevance of epigenetics in the onset and management of type 2 diabetes mellitus. Epigenetics. 2017;12:401–415.
   PubMed Web of Science ®Google Scholar
• Palacios OM, Kramer M, Maki KC. Diet and prevention of type 2 diabetes mellitus: beyond weight loss and exercise. Expert Rev Endocrinol Metab. 2019;14:1–12.
   PubMed Web of Science ®Google Scholar
• Marfella R, Sardu C, Calabrò P, et al. Non-ST-elevation myocardial infarction outcomes in patients with type 2 diabetes with non-obstructive coronary artery stenosis: effects of incretin treatment. Diabetes Obes Metab. 2018;20:723–729.
   PubMed Web of Science ®Google Scholar
• Marfella R, Rizzo MR, Siniscalchi M, et al. Peri-procedural tight glycemic control during early percutaneous coronary intervention up-regulates endothelial progenitor cell level and differentiation during acute ST-elevation myocardial infarction: effects on myocardial salvage. Int J Cardiol. 2013;168:3954–3962.
   PubMed Web of Science ®Google Scholar
• Marzuillo P, Bellini G, Punzo F, et al. Association between 14 bp insertion/deletion HLA-G functional polymorphism and insulin resistance in a cohort of Italian children with obesity. Pediatr Diabetes. 2018;19:1357–1361.
   PubMed Web of Science ®Google Scholar
• García-González IJ, Valle Y, Rivas F, et al. The 14 bp Del/Ins HLA-G polymorphism is related with high blood pressure in acute coronary syndrome and type 2 diabetes mellitus. Biomed Res Int. 2014;2014:898159.
   PubMed Web of Science ®Google Scholar
• Solini A, Muscelli E, Stignani M, et al. Soluble human leukocyte antigen-g expression and glucose tolerance in subjects with different degrees of adiposity. J Clin Endocrinol Metab. 2010;95:3342–3346.
   PubMed Web of Science ®Google Scholar
• Farahvar S, Walfisch A, Sheiner E. Gestational diabetes risk factors and long-term consequences for both mother and offspring: a literature review. Expert Rev Endocrinol Metab. 2019;14:63–74.
   PubMed Web of Science ®Google Scholar
• Martinetti M, Beneventi F, Capittini C, et al. The immunosignature of mother/fetus couples in gestational diabetes mellitus: role of HLA-G 14 bp ins/del and PAPP-A A/C polymorphisms in the uterine inflammatory milieu. Dis Markers. 2017;2017:4254750.
   PubMed Web of Science ®Google Scholar
• Beneventi F, Simonetta M, Locatelli E, et al. Temporal variation in soluble human leukocyte antigen-G (sHLA-G) and pregnancy-associated plasma protein A (PAPP-A) in pregnancies complicated by gestational diabetes mellitus and in controls. Am J Reprod Immunol. 2014;72:413–421.
   PubMed Web of Science ®Google Scholar
• Boiocchi C, Bozzini S, Zorzetto M, et al. Association between two polymorphisms in the HLA-G gene and angiographic coronary artery disease. Mol Med Rep. 2012;5:1141–1145.
   PubMed Web of Science ®Google Scholar
• Zidi I, Kharrat N, Abdelhedi R, et al. Nonclassical human leukocyte antigen (HLA-G, HLA-E,and HLA-F) in coronary artery disease. Hum Immunol. 2016;77:325–329.
   PubMed Web of Science ®Google Scholar
• Feinberg AP. The key role of epigenetics in human disease prevention and mitigation. N Engl J Med. 2018;378:1323–1334.
   PubMed Web of Science ®Google Scholar
• Zullo A, Sommese L, Nicoletti G, et al. Epigenetics and type 1 diabetes: mechanisms and translational applications. Transl Res. 2017;185:85–93.
   PubMed Web of Science ®Google Scholar
• Napoli C, Infante T, Casamassimi A. Maternal-foetal epigenetic interactions in the beginning of cardiovascular damage. Cardiovasc Res. 2011;92:367–374.
   PubMed Web of Science ®Google Scholar
• Napoli C, Crudele V, Soricelli A, et al. Primary prevention of atherosclerosis: a clinical challenge for the reversal of epigenetic mechanisms? Circulation. 2012;125:2363–2373.
   PubMed Web of Science ®Google Scholar
• Schiano C, Vietri MT, Grimaldi V, et al. Epigenetic-related therapeutic challenges in cardiovascular disease. Trends Pharmacol Sci. 2015;36:226–235.
   PubMed Web of Science ®Google Scholar
• Grimaldi V, Zullo A, Donatelli F, et al. Potential clinical benefits of cell therapy in coronary heart disease: an update. J Thorac Dis. 2018;10:S2412–S2422.
   PubMed Web of Science ®Google Scholar
• Grimaldi V, Vietri MT, Schiano C, et al. Epigenetic reprogramming in atherosclerosis. Curr Atheroscler Rep. 2015;17:476.
   PubMed Web of Science ®Google Scholar
• Holling TM, Bergevoet MW, Wierda RJ, et al. Genetic and epigenetic control of the major histocompatibility complex class Ib gene HLA-G in trophoblast cell lines. Ann N Y Acad Sci. 2009;1173:538–544.
   PubMed Web of Science ®Google Scholar
• Guillaudeux T, Rodriguez AM, Girr M, et al. Methylation status and transcriptional expression of the MHC class I loci in human trophoblast cells from term placenta. J Immunol. 1995;154:3283–3299.
   PubMed Web of Science ®Google Scholar
• Boucraut J, Guillaudeux T, Alizadeh M, et al. HLA-E is the only class I gene that escapes CpG methylation and is transcriptionally active in the trophoblast-derived human cell line JAR. Immunogenetics. 1993;38:117–130.
   PubMed Web of Science ®Google Scholar
• Poláková K, Bandzuchová E, Kuba D, et al. Demethylating agent 5-aza-2ʹ-deoxycytidine activates HLA-G expression in human leukemia cell lines. Leuk Res. 2009;33:518–524.
   PubMed Web of Science ®Google Scholar
• Yan WH, Lin AF, Chang CC, et al. Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2ʹ-deoxycytidine. Cell Res. 2005;15:523–531.
   PubMed Web of Science ®Google Scholar
• Moreau P, Mouillot G, Rousseau P, et al. HLA-G gene repression is reversed by demethylation. Proc Natl Acad Sci U S A. 2003;100:1191–1196.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Ponde CK, Rajani RM, et al. Differential methylation pattern in patients with coronary artery disease: pilot study. Mol Biol Rep. 2018. DOI:10.1007/s11033-018-4507-y
   Web of Science ®Google Scholar
• Li X, Zhang Q, Shi Q, et al. Demethylase KDM6A epigenetically promotes IL-6 and IFN-β production in macrophages. J Autoimmun. 2017;80:85–94.
   PubMed Web of Science ®Google Scholar
• Menche J, Sharma A, Kitsak M, et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science. 2015;347:1257601.
   PubMed Web of Science ®Google Scholar
• Cheng F, Desai RJ, Handy DE, et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun. 2018;9:2691.
   PubMed Web of Science ®Google Scholar
• Napoli C, Benincasa G, Loscalzo J. Epigenetic inheritance underlying pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2019;39:653–664ATVBAHA118312262.
   PubMed Web of Science ®Google Scholar
• Haghighi A, Krier JB, Toth-Petroczy A, et al. Undiagnosed diseases network, Brigham and Women’s Hospital facebase project, Brigham Genomic Medicine (BGM). An integrated clinical program and crowdsourcing strategy for genomic sequencing and Mendelian disease gene discovery. NPJ Genom Med. 2018;3:21.
   PubMed Web of Science ®Google Scholar
• Montanucci P, Alunno A, Basta G, et al. Restoration of T cell substes of patients with type 1 diabetes mellitus by microencapsulated human umbilical cord wharton jelly-derived mesenchymal stem cells: an in vitro study. Clin Immunol. 2016;163:34–41.
   PubMed Web of Science ®Google Scholar
• Stamou P, Marioli D, Patmanidi AL, et al. A Simple in vitro generation of human leukocyte antigen-G-expressing T-regulatory cells through pharmacological hypomethylation for adoptive cellular immunotherapy against graft-versus-host disease. Cytotherapy. 2017;19:521–530.
   PubMed Web of Science ®Google Scholar
• Fons P, Chabot S, Cartwright JE, et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood. 2006;108:2608–2615.
   PubMed Web of Science ®Google Scholar
• Scognamiglio M, Costa D, Sorriento A, et al. Current therapy and nutraceuticals for the treatment of patients with dyslipidemias. Curr Pharm Des. 2019;25:85-95. DOI:10.2174/1381612825666190130101108.
   Web of Science ®Google Scholar
• Rochlani Y, Kattoor AJ, Pothineni NV, et al. Balancing primary prevention and statin-induced diabetes mellitus prevention. Am J Cardiol. 2017;120:1122–1128.
   PubMed Web of Science ®Google Scholar